1 / 1

Oncologists’ Views about the Treatments and Care Associated with Advanced varian Cancer

Oncologists’ Views about the Treatments and Care Associated with Advanced varian Cancer Jenkins V 1 , Banerjee S 2 , Ledermann J 3 , Gore M 2 , Catt S 1 , Monson K 1 , Fallowfield L 1

keefe-bradley
Download Presentation

Oncologists’ Views about the Treatments and Care Associated with Advanced varian Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Oncologists’ Views about the Treatments and Care Associated with Advanced varian Cancer Jenkins V1, Banerjee S2 , Ledermann J3 , Gore M2, Catt S1,Monson K1, Fallowfield L1 1SHORE-C University of Sussex, 2The Royal Marsden NHS Foundation Trust London, 3 University College London Background The management of ovarian cancer (OC) involves a multidisciplinary approach and depends on factors including histological subtype, grade, stage of the cancer and performance status. Treatment is essentially palliative and aims to reduce the symptoms of disease without creating too many extra burdens and iatrogenic harms. Surgery together with 1st & 2nd line chemotherapy is standard practice, but there are few published data on the variations in practice across the UK. Method Online survey between October & December 2011 to canvass opinions from UK oncologists about their management of women with advanced OC. This survey was carried out prior to the Cancer Drugs Fund decision about bevacizumab. The survey has 5 sections:- Demographics: plus perceptions of most troubling presenting symptoms for OC Routine NHS care (Non Trial Patients): 1st, 2ndline treatments & subsequent therapies Maintenance therapy: plus opinions about minimum gain required for PFS and OS Clinical trial participation Supportive care Additionally, we are interviewing 200 patients about their experiences of treatment and management of their disease in the ADV CATEstudy (Advanced Ovarian Cancer: Care & Treatment Experiences). See Poster # B142 • Section 3: Maintenance therapy • If available would you offer maintenance therapy based on:- • Progression Free Survival (PFS): 50/60 (83%)Yes • Overall Survival (OS): 60/60 (100%) Yes Section 4: Clinical trial participation 59/60 (98%) cliniciansactive in clinical trials 21/59(36%) conduct early phase trials 29/32 (91%) refer 1-4 patients per year for early phase trials • Section 2: Routine NHS care (non-trial) • 63/65 (97%) conducted regular follow up clinics • 43/66 (65%) measured routine CA125 blood levels • “Which agents do you most commonly use in routine NHS care?” • carboplatin with paclitaxel 56/66 (85%) • Summary: • Treatment for OC across UK varies and main triggers for change in management are also inconsistent • Not all routinely measure CA125 at follow up • Doctors’ perceptions of benefits they think worthwhile differ from those they believe their patients hold • Supportive interventions for worst symptoms of disease and treatment side effects are needed Acknowledgement: Roche UK unrestricted educational grant.

More Related